Prothena Corporation PLC (PRTA) Shares Sold by Jennison Associates LLC

Jennison Associates LLC lessened its stake in Prothena Corporation PLC (NASDAQ:PRTA) by 0.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 410,718 shares of the biotechnology company’s stock after selling 1,185 shares during the period. Jennison Associates LLC owned about 1.07% of Prothena Corporation PLC worth $26,602,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of PRTA. BlackRock Inc. increased its stake in shares of Prothena Corporation PLC by 95,458.7% in the first quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock worth $152,526,000 after buying an additional 2,731,073 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Prothena Corporation PLC by 186.0% during the second quarter. Westfield Capital Management Co. LP now owns 684,160 shares of the biotechnology company’s stock valued at $37,027,000 after purchasing an additional 444,966 shares during the last quarter. Woodford Investment Management Ltd increased its stake in Prothena Corporation PLC by 2.6% during the second quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock valued at $616,991,000 after purchasing an additional 294,213 shares during the last quarter. PointState Capital LP bought a new stake in Prothena Corporation PLC during the second quarter valued at $14,748,000. Finally, State Street Corp increased its stake in Prothena Corporation PLC by 10.6% during the second quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock valued at $63,932,000 after purchasing an additional 113,193 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/11/16/prothena-corporation-plc-prta-shares-sold-by-jennison-associates-llc.html.

Prothena Corporation PLC (NASDAQ PRTA) opened at $55.12 on Thursday. Prothena Corporation PLC has a 1-year low of $45.13 and a 1-year high of $70.00.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.04. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. Prothena Corporation PLC had a negative net margin of 562.19% and a negative return on equity of 34.40%. The company’s revenue for the quarter was down 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.26) earnings per share. research analysts expect that Prothena Corporation PLC will post -4.22 earnings per share for the current year.

Several analysts have weighed in on PRTA shares. ValuEngine upgraded shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Deutsche Bank AG set a $73.00 target price on shares of Prothena Corporation PLC and gave the company a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research note on Friday, August 11th. BidaskClub upgraded shares of Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $79.00 target price on shares of Prothena Corporation PLC in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $78.58.

In related news, insider Tara Nickerson sold 17,500 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the sale, the insider now owns 19,500 shares of the company’s stock, valued at $1,240,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher S. Henney sold 900 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $70.00, for a total transaction of $63,000.00. Following the completion of the sale, the director now directly owns 900 shares of the company’s stock, valued at approximately $63,000. The disclosure for this sale can be found here. Insiders sold 29,424 shares of company stock valued at $1,922,787 in the last ninety days. Corporate insiders own 3.10% of the company’s stock.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply